The FDA is well aware of the hundreds, if not thousands, of US based physicians performing regenerative medicine injections.  There is an upcoming hearing with the FDA at the NIH in September to discuss the future regulation of cell based therapies, at which I've been asked to speak. 

It is widely believed by the medical and regulatory community that PRP, aspirated bone marrow concentrate, and non-digested autologous fat will be ok to use on patients for musculoskeletal, joint and spine injuries and chronic degenerative conditions.  This is to be seen. 

SVF is a product created through digestion of autologous fat (from the same patient) with collagenase enzyme.  This is where it seems the FDA may draw a line in the sand, relegating SVF to a drug status.  Minimal manipulation and homologous use are key concepts. Clearance would be through the FDA via drug clearance pathway (5-7 years research, 1 billion+ $).  Requiring massive pharma support.